Breaking Finance News

BidaskClub upgraded Insys Therapeutics Inc (NASDAQ:INSY) to Buy in a report released today.

BidaskClub has upgraded Insys Therapeutics Inc (NASDAQ:INSY) to Buy in a report released on 07/08/2017.

Yesterday Insys Therapeutics Inc (NASDAQ:INSY) traded -1.66% lower at $13.04. The company’s 50-day moving average is $11.86 and its 200-day moving average is $11.42. The last stock close price is up -22.01% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 565,643 shares of the stock were exchanged, down from an average trading volume of 616,547

See Chart Below

Insys Therapeutics Inc (NASDAQ:INSY)

Insys Therapeutics Inc has a 52 week low of $8.70 and a 52 week high of $18.50 The company’s market cap is currently $0.

In addition to BidaskClub reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $24.40 with 1 firm rating the stock a strong buy, 3 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Insys Therapeutics Inc (NASDAQ:INSY)

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.